EyePoint announced significant progress in clinical trials and financial stability, highlighted by the rapid Phase III enrollment for DURAVYU and a strong cash position. However, the company also faced challenges with decreased revenue, increased operating expenses, and a higher net loss. The sentiment of the call reflects optimism about future milestones and the potential market position, but acknowledges the current financial strains due to increased investments in clinical trials.

Company Guidance

During the EyePoint Second Quarter 2025 Financial Results and Recent Corporate Developments Conference Call, significant guidance was provided regarding the company's lead asset, DURAVYU, which is undergoing two Phase III pivotal trials, LUGANO and LUCIA, for wet age-related macular degeneration (wet-AMD). The trials have successfully enrolled over 800 patients, with top line data expected in mid-2026. DURAVYU has demonstrated a robust safety and efficacy profile in Phase II trials, showing statistically non-inferior visual acuity compared to aflibercept while reducing treatment burden by over 80%. EyePoint's financial position is strong, with $256 million in cash and investments, supporting operations until 2027. The company is also preparing for potential commercial success with a newly built 41,000 square foot cGMP manufacturing facility in Northbridge, Massachusetts. Additionally, EyePoint is advancing plans for a pivotal program in diabetic macular edema (DME), following positive results from the Phase II VERONA trial. The company is focusing on maintaining its first-to-market position among investigational sustained release therapies for wet-AMD.

Rapid Phase III Enrollment for DURAVYU

EyePoint successfully completed full enrollment in both Phase III LUGANO and LUCIA trials for DURAVYU in wet-AMD ahead of schedule, with over 800 patients enrolled, positioning the company for top line data in mid-2026.

Strong Financial Position

EyePoint ended Q2 2025 with $256 million in cash and investments, extending the cash runway into 2027, well beyond pivotal wet-AMD data in 2026.

Construction of cGMP Manufacturing Facility

EyePoint completed a state-of-the-art 41,000 square foot cGMP manufacturing facility in Northbridge, Massachusetts to support commercial production of DURAVYU.

Positive Phase II Results for DME

EyePoint reported highly positive results in the Phase II VERONA trial in diabetic macular edema (DME), which supports a pivotal program in this second blockbuster indication.

EyePoint Pharmaceuticals (EYPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EYPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.77 / -	-0.54	―	―	―
Aug 06, 2025	2025 (Q2)	-0.82 / -0.85	-0.58	-46.55% (-0.27)	―
May 07, 2025	2025 (Q1)	-0.67 / -0.65	-0.55	-18.18% (-0.10)	―
Mar 05, 2025	2024 (Q4)	-0.49 / -0.64	-0.33	-93.94% (-0.31)	―
Nov 07, 2024	2024 (Q3)	-0.55 / -0.54	-0.33	-63.64% (-0.21)	―	―
Aug 07, 2024	2024 (Q2)	-0.51 / -0.58	-0.61	4.92% (+0.03)	―	―
May 08, 2024	2024 (Q1)	-0.40 / -0.55	-0.56	1.79% (+0.01)	―	―
Mar 07, 2024	2023 (Q4)	-0.49 / -0.33	-1.16	71.55% (+0.83)	―
Nov 01, 2023	2023 (Q3)	-0.50 / -0.33	-0.49	32.65% (+0.16)	―
Aug 02, 2023	2023 (Q2)	1.38 / -0.61	-0.52	-17.31% (-0.09)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EYPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$10.89	$10.58	-2.85%
May 07, 2025	$6.25	$6.09	-2.56%
Mar 05, 2025	$6.08	$6.58	+8.22%
Nov 07, 2024	$12.08	$11.59	-4.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Eyepoint Pharma (EYPT) report earnings?

Eyepoint Pharma (EYPT) is schdueled to report earning on Oct 29, 2025, TBA (Confirmed).

What is Eyepoint Pharma (EYPT) earnings time?

Eyepoint Pharma (EYPT) earnings time is at Oct 29, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EYPT EPS forecast?

EYPT EPS forecast for the fiscal quarter 2025 (Q3) is -0.77.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing